Factor Xa

Catalyst has identified Factor Xa variants that have enhanced potency, improved safety, and superior duration of action in preclinical models of bleeding compared with a competing Factor Xa in clinical development.

Catalyst believes that a safe and effective Factor Xa product has the potential to be used both to treat individuals with hemophilia and to reduce blood loss in trauma and surgery in people with normal coagulation systems and clotting activity or those who are taking anti-platelet agents or anticoagulants.

Catalyst’s FXa program has reached the lead candidate stage of research and is available for partnering.